← All trials
NCT06743503
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- May 21, 2028
- Completion date
- Jul 31, 2030
- First posted
- Dec 20, 2024
- Last posted
- Dec 20, 2024
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IASO Pharma Inc.Lead sponsor
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.